Jupiter Neurosciences (JUNS) Competitors $0.32 -0.01 (-3.70%) Closing price 03:59 PM EasternExtended Trading$0.32 +0.01 (+1.56%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock JUNS vs. TLPH, IXHL, NTRB, TELO, and PSTVShould you buy Jupiter Neurosciences stock or one of its competitors? MarketBeat compares Jupiter Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jupiter Neurosciences include Talphera (TLPH), Incannex Healthcare (IXHL), Nutriband (NTRB), Telomir Pharmaceuticals (TELO), and Plus Therapeutics (PSTV). These companies are all part of the "med - drugs" industry. JUNS vs. TLPHJUNS vs. IXHLJUNS vs. NTRBJUNS vs. TELOJUNS vs. PSTVHow does Jupiter Neurosciences compare to Talphera?Talphera (NASDAQ:TLPH) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings. Does the media favor TLPH or JUNS? In the previous week, Talphera had 9 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 11 mentions for Talphera and 2 mentions for Jupiter Neurosciences. Talphera's average media sentiment score of 0.48 beat Jupiter Neurosciences' score of -1.50 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Jupiter Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative Which has stronger valuation and earnings, TLPH or JUNS? Jupiter Neurosciences has lower revenue, but higher earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$30K1,439.01-$14.29M-$0.31N/AJupiter Neurosciences$20K580.48-$8.65M-$0.27N/A Do analysts prefer TLPH or JUNS? Talphera currently has a consensus price target of $3.00, indicating a potential upside of 260.66%. Given Talphera's stronger consensus rating and higher probable upside, equities analysts plainly believe Talphera is more favorable than Jupiter Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is TLPH or JUNS more profitable? Talphera's return on equity of -92.98% beat Jupiter Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -92.98% -53.22% Jupiter Neurosciences N/A -1,314.62%-228.63% Do institutionals and insiders have more ownership in TLPH or JUNS? 37.7% of Talphera shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 50.8% of Jupiter Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, TLPH or JUNS? Talphera has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. SummaryTalphera beats Jupiter Neurosciences on 10 of the 15 factors compared between the two stocks.How does Jupiter Neurosciences compare to Incannex Healthcare?Jupiter Neurosciences (NASDAQ:JUNS) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts prefer JUNS or IXHL? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media prefer JUNS or IXHL? In the previous week, Incannex Healthcare had 2 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 4 mentions for Incannex Healthcare and 2 mentions for Jupiter Neurosciences. Incannex Healthcare's average media sentiment score of 0.88 beat Jupiter Neurosciences' score of -1.50 indicating that Incannex Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jupiter Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative Incannex Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in JUNS or IXHL? 0.4% of Incannex Healthcare shares are owned by institutional investors. 50.8% of Jupiter Neurosciences shares are owned by insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better valuation & earnings, JUNS or IXHL? Jupiter Neurosciences has higher earnings, but lower revenue than Incannex Healthcare. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJupiter Neurosciences$20K580.48-$8.65M-$0.27N/AIncannex Healthcare$90K492.10-$46.88M-$8.41N/A Which has more risk and volatility, JUNS or IXHL? Jupiter Neurosciences has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7.22, indicating that its share price is 622% more volatile than the broader market. Is JUNS or IXHL more profitable? Incannex Healthcare's return on equity of -88.67% beat Jupiter Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Jupiter NeurosciencesN/A -1,314.62% -228.63% Incannex Healthcare N/A -88.67%-83.39% SummaryIncannex Healthcare beats Jupiter Neurosciences on 8 of the 12 factors compared between the two stocks.How does Jupiter Neurosciences compare to Nutriband?Jupiter Neurosciences (NASDAQ:JUNS) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Do analysts rate JUNS or NTRB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Is JUNS or NTRB more profitable? Jupiter Neurosciences has a net margin of 0.00% compared to Nutriband's net margin of -403.98%. Nutriband's return on equity of -118.33% beat Jupiter Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Jupiter NeurosciencesN/A -1,314.62% -228.63% Nutriband -403.98%-118.33%-101.92% Do institutionals and insiders have more ownership in JUNS or NTRB? 19.7% of Nutriband shares are owned by institutional investors. 50.8% of Jupiter Neurosciences shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, JUNS or NTRB? Nutriband has higher revenue and earnings than Jupiter Neurosciences. Nutriband is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJupiter Neurosciences$20K580.48-$8.65M-$0.27N/ANutriband$2.04M20.96-$8.23M-$2.60N/A Does the media refer more to JUNS or NTRB? In the previous week, Jupiter Neurosciences had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for Jupiter Neurosciences and 1 mentions for Nutriband. Nutriband's average media sentiment score of 0.00 beat Jupiter Neurosciences' score of -1.50 indicating that Nutriband is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jupiter Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative Nutriband 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, JUNS or NTRB? Jupiter Neurosciences has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. SummaryNutriband beats Jupiter Neurosciences on 8 of the 14 factors compared between the two stocks.How does Jupiter Neurosciences compare to Telomir Pharmaceuticals?Telomir Pharmaceuticals (NASDAQ:TELO) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Does the media refer more to TELO or JUNS? In the previous week, Jupiter Neurosciences had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 2 mentions for Jupiter Neurosciences and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 3.00 beat Jupiter Neurosciences' score of -1.50 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Telomir Pharmaceuticals Very Positive Jupiter Neurosciences Very Negative Which has more volatility and risk, TELO or JUNS? Telomir Pharmaceuticals has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market. Do analysts rate TELO or JUNS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable valuation & earnings, TELO or JUNS? Jupiter Neurosciences has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$10.41M-$0.29N/AJupiter Neurosciences$20K580.48-$8.65M-$0.27N/A Is TELO or JUNS more profitable? Telomir Pharmaceuticals' return on equity of -201.23% beat Jupiter Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -201.23% -172.71% Jupiter Neurosciences N/A -1,314.62%-228.63% SummaryJupiter Neurosciences beats Telomir Pharmaceuticals on 6 of the 11 factors compared between the two stocks.How does Jupiter Neurosciences compare to Plus Therapeutics?Jupiter Neurosciences (NASDAQ:JUNS) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Which has better valuation & earnings, JUNS or PSTV? Jupiter Neurosciences has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJupiter Neurosciences$20K580.48-$8.65M-$0.27N/APlus Therapeutics$5.21M7.70-$22.39M-$2.30N/A Do insiders and institutionals believe in JUNS or PSTV? 3.3% of Plus Therapeutics shares are owned by institutional investors. 50.8% of Jupiter Neurosciences shares are owned by insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is JUNS or PSTV more profitable? Jupiter Neurosciences has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Jupiter Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Jupiter NeurosciencesN/A -1,314.62% -228.63% Plus Therapeutics -230.24%-198.48%-73.13% Does the media refer more to JUNS or PSTV? In the previous week, Plus Therapeutics had 5 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 7 mentions for Plus Therapeutics and 2 mentions for Jupiter Neurosciences. Plus Therapeutics' average media sentiment score of -0.13 beat Jupiter Neurosciences' score of -1.50 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jupiter Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative Plus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, JUNS or PSTV? Jupiter Neurosciences has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Do analysts recommend JUNS or PSTV? Plus Therapeutics has a consensus price target of $58.00, indicating a potential upside of 894.85%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Jupiter Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 SummaryPlus Therapeutics beats Jupiter Neurosciences on 9 of the 16 factors compared between the two stocks. Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JUNS vs. The Competition ExportMetricJupiter NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.06M$2.99B$6.25B$12.23BDividend YieldN/A1.96%2.80%5.32%P/E Ratio-1.1917.0420.7925.05Price / Sales580.48251.21531.2172.69Price / CashN/A57.1543.0954.25Price / Book-4.004.399.816.83Net Income-$8.65M$74.99M$3.55B$335.69M7 Day Performance-3.12%-4.89%-2.07%-2.03%1 Month Performance-26.81%-8.30%-3.90%-1.90%1 Year Performance-45.31%28.66%29.39%27.36% Jupiter Neurosciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JUNSJupiter Neurosciences0.5303 of 5 stars$0.32-3.7%N/A-43.2%$12.06M$20KN/A5Negative NewsEarnings ReportUpcoming EarningsGap UpTLPHTalphera3.4866 of 5 stars$0.90+5.1%$3.00+232.9%+58.2%$46.78M$28KN/A19News CoverageEarnings ReportIXHLIncannex Healthcare0.7233 of 5 stars$3.85-1.3%N/A-51.4%$45.94MN/AN/A3Upcoming EarningsNTRBNutriband0.1863 of 5 stars$3.50-4.1%N/A-38.5%$42.56M$2.04MN/A10Positive NewsTELOTelomir Pharmaceuticals1.5961 of 5 stars$1.23-2.4%N/A-52.4%$42.29MN/AN/A1Earnings ReportGap Up Related Companies and Tools Related Companies TLPH Competitors IXHL Competitors NTRB Competitors TELO Competitors PSTV Competitors SCYX Competitors TPST Competitors MRKR Competitors TXMD Competitors VYNE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JUNS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
